Therapeutic vaccines and cancer: focus on DPX-0907

Mohan Karkada,1,2 Neil L Berinstein,3 Marc Mansour1 1ImmunoVaccine Inc, 2Department of Microbiology/Immunology, Dalhousie University, Halifax, NS, Canada; 3Ontario Institute for Cancer Research, Toronto, ON, Canada Abstract: In an attempt to significantly enhance immunogenicity of peptide cancer v...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karkada M, Berinstein NL, Mansour M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/cbabb54c5a534797a117f9f3f9a41636
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cbabb54c5a534797a117f9f3f9a41636
record_format	dspace
spelling	oai:doaj.org-article:cbabb54c5a534797a117f9f3f9a416362021-12-02T02:32:26ZTherapeutic vaccines and cancer: focus on DPX-09071177-5475https://doaj.org/article/cbabb54c5a534797a117f9f3f9a416362014-02-01T00:00:00Zhttp://www.dovepress.com/therapeutic-vaccines-and-cancer-focus-on-dpx-0907-a15754https://doaj.org/toc/1177-5475 Mohan Karkada,1,2 Neil L Berinstein,3 Marc Mansour1 1ImmunoVaccine Inc, 2Department of Microbiology/Immunology, Dalhousie University, Halifax, NS, Canada; 3Ontario Institute for Cancer Research, Toronto, ON, Canada Abstract: In an attempt to significantly enhance immunogenicity of peptide cancer vaccines, we developed a novel non-emulsion depot-forming vaccine platform called DepoVax™ (DPX). Human leukocyte antigen (HLA)-A2 restricted peptides naturally presented by cancer cells were used as antigens to create a therapeutic cancer vaccine, DPX-0907. In a phase I clinical study, the safety and immune-activating potential of DPX-0907 in advanced-stage breast, ovarian, and prostate cancer patients were examined, following encouraging results in HLA-A2 transgenic mice. The DPX-0907 vaccine was shown to be safe and well tolerated, with injection-site reactions being the most commonly reported adverse event. Vaccinated cancer patients exhibited a 61% immune response rate, with higher response rates in the breast and ovarian cancer patient cohorts. In keeping with the higher immune efficacy of this vaccine platform, antigen-specific responses were detected in 73% of immune responders after just one vaccination. In 83% of responders, peptide-specific T-cells were detected at two or more time points post-vaccination, with 64% of these patients showing evidence of immune persistence. Immune monitoring also demonstrated the generation of antigen-specific T-cell memory, with the ability to secrete multiple type 1 cytokines. The novel DPX formulation promotes multifunctional effector/memory responses to peptide-based tumor-associated antigens. The data support the capacity of DPX-0907 to elicit type-1 biased immune responses, warranting further clinical development of the vaccine. In this review, we discuss the rationale for developing DPX-based therapeutic cancer vaccine(s), with a focus on DPX-0907, aimed at inducing efficient anti-tumor immunity that may eventually be shown to prolong patient survival. Keywords: immunotherapy, DepoVax™, cancer vaccine, DPX-0907Karkada MBerinstein NLMansour MDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2014, Iss default, Pp 27-38 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Karkada M Berinstein NL Mansour M Therapeutic vaccines and cancer: focus on DPX-0907
description	Mohan Karkada,1,2 Neil L Berinstein,3 Marc Mansour1 1ImmunoVaccine Inc, 2Department of Microbiology/Immunology, Dalhousie University, Halifax, NS, Canada; 3Ontario Institute for Cancer Research, Toronto, ON, Canada Abstract: In an attempt to significantly enhance immunogenicity of peptide cancer vaccines, we developed a novel non-emulsion depot-forming vaccine platform called DepoVax™ (DPX). Human leukocyte antigen (HLA)-A2 restricted peptides naturally presented by cancer cells were used as antigens to create a therapeutic cancer vaccine, DPX-0907. In a phase I clinical study, the safety and immune-activating potential of DPX-0907 in advanced-stage breast, ovarian, and prostate cancer patients were examined, following encouraging results in HLA-A2 transgenic mice. The DPX-0907 vaccine was shown to be safe and well tolerated, with injection-site reactions being the most commonly reported adverse event. Vaccinated cancer patients exhibited a 61% immune response rate, with higher response rates in the breast and ovarian cancer patient cohorts. In keeping with the higher immune efficacy of this vaccine platform, antigen-specific responses were detected in 73% of immune responders after just one vaccination. In 83% of responders, peptide-specific T-cells were detected at two or more time points post-vaccination, with 64% of these patients showing evidence of immune persistence. Immune monitoring also demonstrated the generation of antigen-specific T-cell memory, with the ability to secrete multiple type 1 cytokines. The novel DPX formulation promotes multifunctional effector/memory responses to peptide-based tumor-associated antigens. The data support the capacity of DPX-0907 to elicit type-1 biased immune responses, warranting further clinical development of the vaccine. In this review, we discuss the rationale for developing DPX-based therapeutic cancer vaccine(s), with a focus on DPX-0907, aimed at inducing efficient anti-tumor immunity that may eventually be shown to prolong patient survival. Keywords: immunotherapy, DepoVax™, cancer vaccine, DPX-0907
format	article
author	Karkada M Berinstein NL Mansour M
author_facet	Karkada M Berinstein NL Mansour M
author_sort	Karkada M
title	Therapeutic vaccines and cancer: focus on DPX-0907
title_short	Therapeutic vaccines and cancer: focus on DPX-0907
title_full	Therapeutic vaccines and cancer: focus on DPX-0907
title_fullStr	Therapeutic vaccines and cancer: focus on DPX-0907
title_full_unstemmed	Therapeutic vaccines and cancer: focus on DPX-0907
title_sort	therapeutic vaccines and cancer: focus on dpx-0907
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/cbabb54c5a534797a117f9f3f9a41636
work_keys_str_mv	AT karkadam therapeuticvaccinesandcancerfocusondpx0907 AT berinsteinnl therapeuticvaccinesandcancerfocusondpx0907 AT mansourm therapeuticvaccinesandcancerfocusondpx0907
_version_	1718402437916655616

Therapeutic vaccines and cancer: focus on DPX-0907

Ejemplares similares